AdvanTIG-105: Phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors.

被引：0
|
作者：
Frentzas, Sophia
Meniawy, Tarek
Kao, Steven Chuan-Hao
Wang, Ruihua
Zuo, Yunxia
Zheng, Hao
Tan, Wei
机构：
[1] Monash Hlth, Med Oncol, Melbourne, Vic, Australia
[2] Monash Univ, Sch Med & Hlth Sci, Melbourne, Vic, Australia
[3] Edith Cowan Univ, Joondalup, WA, Australia
[4] Univ Western Australia, Sch Med, Crawley, WA, Australia
[5] Sir Charles Gairdner Hosp, Dept Med Oncol, Nedlands, WA, Australia
[6] Univ Sydney, Sch Med, Chris OBrien Life House, Sydney, NSW, Australia
[7] BeiGene Ltd, Shanghai, Peoples R China
[8] BeiGene USA Inc, San Mateo, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.2583
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2583
引用
收藏
页数：2
相关论文
共 50 条
  • [1] AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors
    Frentzas, Sophia
    Kao, Steven
    Gao, Rang
    Zheng, Hao
    Rizwan, Ahsan
    Budha, Nageshwar
    Pedroza, Luz de la Hoz
    Tan, Wei
    Meniawy, Tarek
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (10)
  • [2] PERIPHERAL PHARMACODYNAMIC (PD) EFFECTS OF OCIPERLIMAB (OCI) IN COMBINATION WITH TISLELIZUMAB (TIS) IN PATIENTS WITH ADVANCED SOLID TUMORS: ADVANTIG-105 PHASE 1 DOSEESCALATION STUDY
    Tan, Wei
    Shi, Yang
    Yan, Han
    Shen, Zhirong
    Budha, Nageshwar
    Rizwan, Ahsan
    Huang, Ruiqi
    Zheng, Hao
    Gao, Rang
    Frentzas, Sophia
    Kao, Steven
    Meniawy, Tarek
    Zhang, Yun
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A799 - A799
  • [3] Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors
    Bendell, Johanna C.
    Bedard, Philippe
    Bang, Yung-Jue
    LoRusso, Patricia
    Hodi, Stephen
    Gordon, Michael
    D'Angelo, Sandra
    Desai, Jayesh
    Garralda, Elena
    Italiano, Antoine
    Myung-Ju Ahn
    Cervantes, Andres
    Wainberg, Zev
    Calvo, Emiliano
    Gil-Martin, Marta
    Martinez-Garcia, Maria
    Bahleda, Rastilav
    Cassier, Philippe
    Delord, Jean-Pierre
    Prawira, Amy
    Melero, Ignacio
    Emens, Leisha
    Romano, Emanuela
    Miller, Karen
    Hsieh, Robert W.
    Xue, Cloris
    Morrissey, Kari
    Twomey, Patrick
    Gash, Kelly
    Patil, Namrata S.
    Grogan, Jane
    Meng, Raymond
    Cho, Byoung
    Kim, Tae Won
    CANCER RESEARCH, 2020, 80 (16)
  • [4] AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab plus Tislelizumab in Patients with Metastatic NSCLC
    Kumar, R.
    Kim, S. H.
    Zhong, D.
    Lu, S.
    Cheng, Y.
    Chen, M.
    Cho, E.
    Clay, T.
    Kang, J. -H.
    Lee, G. -W.
    Sun, M.
    Shim, B. -Y.
    Spigel, D. R.
    Yang, T. -Y.
    Wang, Q.
    Chang, G. -C.
    Yu, G.
    Wang, R.
    Luo, X.
    Zheng, H.
    Gao, R.
    Kim, H. R.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S375 - S376
  • [5] AdvanTIG-202: A phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer.
    Wu, Lingying
    Wang, Peng-Hui
    Hsiao, Sheng-Yen
    Chang, Chih-Long
    Kim, Hee Seung
    Lee, Jung-Yun
    Ryu, Sang-Young
    Zuo, Yunxia
    Mu, Xiyan
    Gao, Yujuan
    Yang, Silu
    Lee, Jae-Kwan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with bevacizumab (BEV) for advanced solid tumors.
    Rosen, Lee S.
    Robert, Francisco
    Matei, Daniela
    Goldman, Jonathan Wade
    Mendelson, David S.
    Chiorean, E. Gabriela
    Strother, Robert Matthew
    Seon, Ben K.
    Alvarez, Delia
    Adams, Bonne J.
    Theuer, Charles P.
    Gordon, Michael S.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumors.
    Berlin, Jordan
    Ramanathan, Ramesh K.
    Strickler, John H.
    Subramaniam, Deeps Suresh
    Hurwitz, Herbert
    Kang, Yoon-Koo
    Kim, Tae-You
    Shepherd, Stacie Peacock
    Xiong, Hao
    Hetman, Robert
    Nickner, Caroline
    Dudley, Matthew W.
    Giranda, Vincent L.
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors
    Yamamoto, Noboru
    Koyama, Takafumi
    Sato, Jun
    Yoshida, Tatsuya
    Sudo, Kazuki
    Iwasa, Satoru
    Kondo, Shunsuke
    Yonemori, Kan
    Kawasaki, Atsuko
    Satake, Kyoko
    Shibata, Shoyo
    Shimizu, Toshio
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 94 (01) : 109 - 115
  • [9] AdvanTIG-206: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus antiprogrammed cell death protein 1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus (vs) TIS plus BAT1706 as first-line treatment for advanced hepatocellular carcinoma (HCC)
    Fan, Jia
    Ren, Zhenggang
    Hsu, Chiun
    Guo, Yabing
    Song, Tianqiang
    Wang, Wentao
    Chao, Yee
    Gao, Yujuan
    Li, Bai
    Ferro, Salvatore
    Yen, Chia-Jui
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [10] A phase Ib dose-escalation study of TRC105 in combination with bevacizumab for advanced solid tumors
    Mendelson, David S.
    Rosen, Lee S.
    Robert, Francisco
    Chiorean, E. Gabriela
    Goldman, Jonathan Wade
    Seon, Ben K.
    Alvarez, Delia
    Adams, Bonne J.
    Theuer, Charles P.
    Leigh, Bryan R.
    Gordon, Michael S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345